GRAIL, Inc., a healthcare company whose mission is to detect cancer early, recently presented the first results from the interventional PATHFINDER study evaluating Galleri™, a multi-cancer early detection (MCED) blood test. The results, presented at the 2021 ASCO Annual Meeting, support Galleri’s performance in clinical settings. The company also announced that Galleri is now available […]
